Skip to Primary Navigation

Skip to main content

Biotech company avoids DOJ charges after self-reporting payment of bribes

Close up of Mexican Peso banknotes and coins.
Photo: Getty Images

Julie DiMauro

6 min read
 Click to share on Facebook (Opens in new window/tab) Click to share on Twitter (Opens in new window/tab) Click to share on LinkedIn (Opens in new window/tab) Click to share on WhatsApp (Opens in new window/tab)

Lifecore Biomedical, Inc.’s efforts in self-reporting FCPA violations lead to declination decision from DOJ.

Lifecore Biomedical, Inc., formerly known as Landec Corporation, has received a declination with disgorgement from the US Department of Justice (DOJ) for Foreign Corrupt Practices Act (FCPA) violations in Mexico. The company is a biotech firm with its principal offices in California but is incorporated in Delaware.

The DOJ’s declination

, , , , , , , ,

Get full access, free for a month

This is a Premium article. Start your 28-day free trial to continue reading and access all content on GRIP – no payment details required.

Start free trial Sign in

What’s included:

  • Every new article, plus our 5,000+ archive
  • Daily regulatory insight and guidance
  • Exclusive interviews and in-depth analysis
  • Coverage of industry-leading events and conferences
  • All podcasts and videos, featuring industry experts
  • The full set of Rules Navigator tools
  • An ad-free experience